Anti-IgE for chronic asthma in adults and children

Walker, Samantha; Monteil, Michèle; Phelan, Kieran J.; Lasserson, TJ; Walters, EH

doi:10.1002/14651858.cd003559.pub2

Cited by 71 publications

(84 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Evidence suggests that a subset of patients with severe asthma might be insensitive to steroids. 25 Thus the use of steroids in patients who are insensitive might add additional toxicity without the benefit that is realized in other subpopulations. Moreover, we assume equivalency across all ICS preparations.…”

Section: Input Data: Effect Of Ics Therapymentioning

confidence: 99%

“…Baseline input values and parameters for sensitivity analyses are listed in Table I. 2,[25][26][27][28] Reduction in exacerbation rate-The Cochrane Airways Group's review of omalizumab found a 46% reduction in the rate of exacerbation in subjects receiving omalizumab plus an ICS compared with that seen in the subjects receiving an ICS alone. 24 Thus in our base-case analysis we assumed a 46% reduction in the exacerbation rate.…”

Section: Input Data: Effect Of Omalizumab Therapymentioning

confidence: 99%

“…2 Based on this difference in length of exacerbation, we chose to assume a 63% reduction in resource use intensity, which corresponds to a decrease from 12.7 days to 7.8 days. 26 Change in lung function-The systematic review conducted by the Cochrane Airways Group suggests a small improvement in FEV 1 percent predicted 25 associated with omalizumab therapy. The systematic review finds an improvement in FEV 1 percent predicted of 2.9% in subjects treated with omalizumab.…”

Section: Input Data: Effect Of Omalizumab Therapymentioning

confidence: 99%

See 2 more Smart Citations

Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy Model

Paltiel

Kuntz³

et al. 2007

Journal of Allergy and Clinical Immunology

103

View full text Add to dashboard Cite

show abstract

Section: Input Data: Effect Of Ics Therapymentioning

confidence: 99%

Section: Input Data: Effect Of Omalizumab Therapymentioning

confidence: 99%

Section: Input Data: Effect Of Omalizumab Therapymentioning

confidence: 99%

See 1 more Smart Citation

Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy Model

Paltiel

Kuntz³

et al. 2007

Journal of Allergy and Clinical Immunology

103

View full text Add to dashboard Cite

show abstract

“…This action reduces the release of mediators of allergic reactions. Omalizumab has been studied in patients with severe asthma, and it was shown that it is effective as a steroid-sparing drug and in decreasing the frequency of asthma exacerbations [34,35].…”

Section: Biological Treatmentsmentioning

confidence: 99%

Severe Asthma: Moving from Phenotype to Endotype Classification with Updates on Treatment

Noujeim¹,

Bou‐Khalil²

2016

J Nurs Care

View full text Add to dashboard Cite

Asthma has classically been categorized into several phenotypes to address the complexities of this disease. However, phenotypes only cover the clinically relevant aspects of the disease, but do not address the relationship between the disease and its etiology and pathophysiology. This led to the development of the term "endotypes" which links key pathogenic mechanisms with asthma phenotypes, and ultimately leads to better selection of treatment resulting in improved response. Although the exact pathogenesis of asthma is still under investigation, targeted-therapy based on asthma phenotypes and endotypes has shown some success, and the future appears promising for patients suffering from severe asthma since treatment is being tailored according to individual biology. We review in this manuscript the best evidence and updates currently available in the classification and treatment recommendations for severe asthma.

show abstract

“…Further studies into this aspect are needed, especially ones including pediatric patients. 36 Currently, omalizumab is licensed in the United States for patients over 12 years old with persistent moderate or severe asthma who have a positive skin test or in vitro test for an aeroallergen, with poor control using inhaled steroids, and whose total IgE in serum is from 30 to 700 UI/mL. 13,21,37 In the European Community and Brazil, approval is limited to the treatment of severe asthma.…”

Section: Removal Of Ige From Circulation Blocking It From Fixingmentioning

confidence: 99%

Anticorpo monoclonal anti-IgE no tratamento da asma e de outras manifestações relacionadas a doença alérgica

Sarinho¹,

Cruz²

2006

J. Pediatr. (Rio J.)

View full text Add to dashboard Cite

Objectives: To report on the pharmacology, efficacy and safety of omalizumab , a new option for the treatment of asthma and allergic diseases and the first monoclonal anti-IgE antibody approved for clinical use.Sources: MEDLINE, a non-systematic search including reviews and original papers, chosen according to their relevance in the authors opinion.Summary of the findings: The paper emphasizes the central role IgE plays in allergic diseases and the biological rationale for its use, the evidence upon which the current recommendations for the use of anti-IgE in uncontrolled asthma are based and its possible future applications, in addition to the recommendation that in clinical practice doses must be adjusted for weight and serum IgE levels. Omalizumab was approved in Brazil for patients with severe uncontrolled asthma presenting with a positive skin prick test for one or more relevant aeroallergen, or IgE specific to a relevant allergen detected in serum, having a total IgE level of between 30 and 700 UI/mL. For the time being its use should be restricted to patients aged 12 years or more, but there are prospects that it will be licensed for use with children over 6 years old.Conclusions: Some severe asthma cases cannot be controlled with the regular treatment options aimed at preventing symptoms and exacerbations, and so require frequent or prolonged use of systemic corticosteroids. These patients may benefit from treatment with anti-IgE, after a meticulous reevaluation of possible reasons for the failure to control asthma.J Pediatr (Rio J). 2006;82(5 Suppl):S127-32: Omalizumab, anti-IgE, asthma, severe asthma, allergic rhinitis, atopic dermatitis. REVIEW ARTICLE

show abstract

Anti-IgE for chronic asthma in adults and children

Cited by 71 publications

References 33 publications

Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy Model

Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy Model

Severe Asthma: Moving from Phenotype to Endotype Classification with Updates on Treatment

Anticorpo monoclonal anti-IgE no tratamento da asma e de outras manifestações relacionadas a doença alérgica

Contact Info

Product

Resources

About